Amgen Inc.

Corey Reeves

Ning Chen

Jennifer Rebecca Allen

Qingyian Liu

Michael J Frohn

Matthew Paul Bourbeau

Aaron C Siegmund

Longbin Liu

Liping H Pettus

Albert Kudzovi Amegadzie

Vu Van Ma

Paul E Harrington

James A Brown

Wenyuan Qian

Jian Jeffrey Chen

Thomas T Nguyen

Zice Fu

Alexander J Pickrell

Jonathan Dante Low

Clifford Goodman

Alfonso Pozzan

Iain Lingard

Federica Tonelli

Giulia Lattanzi

Sabrina Tassini

The present disclosure provides compounds useful for the inhibition of Delta-5 Desaturase (“D5D”). The compounds have a general Formula 1: wherein the variables of Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, uses of the compounds, and compositions for treatment of, for example, a metabolic or cardiovascular disorder. Further, the disclosure provides intermediates useful in the synthesis of compounds of Formula I.

Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use

The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: 

1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use

The present disclosure provides a class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: (insert Formula I structure) wherein variables W, X, Y, R, R, R, R, R, R, and Rof Formula I are defined herein. This disclosure also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to beta amyloid (A&#x3b2;) plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, and other central nervous system conditions. 

Substituted oxazines as beta-secretase inhibitors

The present disclosure provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: 

Cyclopropyl fused thiazine derivatives as beta-secretase inhibitors and methods of use

The present invention provides a new class of compounds useful for the modulation of beta-secretase enzyme (BACE) activity. The compounds have a general Formula I: wherein variables A, A, A, A, and each of R, R, R, R, R, RRand Rof Formula I, independently, are defined herein. The invention also provides pharmaceutical compositions comprising the compounds, and uses of the compounds and compositions for treatment of disorders and/or conditions related to A&#x3b2; plaque formation and deposition, resulting from the biological activity of BACE. Such BACE mediated disorders include, for example, Alzheimer's Disease, cognitive deficits, cognitive impairments, schizophrenia and other central nervous system conditions. 

Vinyl fluoride cyclopropyl fused thiazin-2-amine compounds as beta-secretase inhibitors and methods of use

Growing community of inventors

Sherman Oaks, CA, United States of America

Corey Reeves